Epidermolysis Bullosa Eb Epidemiology Forecast

"DelveInsight’s ‘Epidermolysis Bullosa (EB)-Epidemiology Forecast–2030’ report delivers an in-depth understanding of the EB, historical and forecasted epidemiology as well as the EB trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Epidermolysis Bullosa (EB) Disease Understanding

Epidermolysis Bullosa (EB) is a group of skin diseases that cause various degrees of skin and mucous membrane fragility. The skin becomes fragile when proteins essential for skin integrity are absent, reduced, or abnormal. It is characterized by blister formation in response to mechanical trauma. EB is generally caused by mutations involving at least 18 genes encoding structural proteins within keratin intermediate filaments, focal adhesions, desmosome cell junctions, and hemidesmosome attachment complexes, which form the intraepidermal adhesion and dermo-epidermal anchoring complex within the basement membrane zone (BMZ) of the skin and mucosae.


There are four major types of EB, depending on the location of the target proteins and level of the blisters: EB simplex (EBS), junctional EB (JEB), dystrophic EB (DEB), and Kindler syndrome.

Epidermolysis Bullosa (EB) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of EB, Diagnosed Prevalent Patient Population of EB, and Type-specific Diagnosed Prevalent Population of EB scenario of EB in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Epidermolysis Bullosa (EB) Detailed Epidemiology Segmentation

  • According to DelveInsight’s, the total prevalent population of EB in seven major markets ranges was 42,355 in 2020.
  • The total diagnosed prevalent cases of EB in the 7MM was 40,238 in 2020.
  • In 2020, there were 26,679 prevalent cases of EB in the United States. In the same years, there were a total of 25,345 diagnosed prevalent cases of EB in the United States. 
  • Epidermolysis Bullosa is of several types, and three major types of Epidermolysis bullosa includes Epidermolysis bullosa simplex (EBS), junctional EB (JEB), and dystrophic EB (DEB). Assessments as per DelveInsight’s analysts show that the majority of cases of EB are EBS in the United States. In 2020, there were 15,207 cases of EBS, 1,267 cases of JEB, and 8,871 cases of DEB in the United States. DEB is further divided as recessive and dominant. 
  • Out of 8,871 cases of DEB in the United States in 2020, 4,654 cases were dominant DEB and 4,217 cases were recessive DEB. 
  • Among the European countries, the United Kingdom had the highest prevalent population of EB with 5,151 cases, followed by Germany which had a prevalent population of 4,971 in 2020. On the other hand, Spain had the lowest prevalent population of 937 in 2020.

Scope of the Report

  • The report covers the descriptive overview of EB, explaining its causes, signs and symptoms, and pathophysiology.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of EB.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of EB, Diagnosed Prevalent Patient Population of EB, and Type-specific Diagnosed Prevalent Population of EB. 

Report Highlights

  • 10-Year Forecast of EB
  • 7MM Coverage 
  • Total Prevalent Cases of EB
  • Diagnosed Prevalent Patient Population of EB
  • Type-specific Diagnosed Prevalent Population of EB

Key Questions Answered

  • What are the disease risk, burden, and unmet needs of EB?
  • What is the historical EB patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of EB at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to EB?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of EB during the forecast period (2021–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?

Reasons to buy

The EB report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM EB epidemiology forecast.
  • The EB epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The EB epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation 
  • Factors driving growth in a specific patient population

1. Key Insights

2. Executive Summary of Epidermolysis Bullosa (EB)

3. Epidermolysis Bullosa (EB) Epidemiology Overview at a Glance

3.1. Epidemiology Share (%) Distribution of Epidermolysis Bullosa (EB) in 2018

3.2. Epidemiology Share (%) Distribution of Epidermolysis Bullosa (EB) in 2030

4. Epidermolysis Bullosa (EB): Disease Background and Overview

4.1. Introduction

4.2. Causes of Epidermolysis Bullosa

4.3. Signs and Symptoms of Epidermolysis Bullosa

4.4. Classification of Epidermolysis Bullosa

4.5. Pathophysiology of Epidermolysis Bullosa

4.6. Genetic Bases of Epidermolysis Bullosa

4.7. Diagnosis of Epidermolysis Bullosa

4.7.1. Diagnostic Guidelines

5. Epidemiology and Patient Population

5.1. Key Findings

5.2. Epidemiology Methodology

5.3. 7MM Total Prevalent Patient Population of Epidermolysis Bullosa

5.4. 7MM Diagnosed Prevalent Patient Population of Epidermolysis Bullosa

5.5. 7MM Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa

6. Country Wise-Epidemiology of Epidermolysis Bullosa

6.1. United States Epidemiology

6.1.1. Assumptions and Rationale

6.1.2. Total Prevalent Cases of Epidermolysis Bullosa in the United States

6.1.3. Diagnosed Prevalence of Epidermolysis Bullosa in the United States

6.1.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in the United States

6.2. EU5 Epidemiology

6.2.1. Germany

6.2.1.1. Assumptions and Rationale

6.2.1.2. Total Prevalent Cases of Epidermolysis Bullosa in Germany

6.2.1.3. Diagnosed Prevalence of Epidermolysis Bullosa in Germany

6.2.1.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Germany

6.2.2. France

6.2.2.1. Assumptions and Rationale

6.2.2.2. Total Prevalent Cases of Epidermolysis Bullosa in France

6.2.2.3. Diagnosed Prevalence of Epidermolysis Bullosa in France

6.2.2.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in France

6.2.3. Italy

6.2.3.1. Assumptions and Rationale

6.2.3.2. Total Prevalent Cases of Epidermolysis Bullosa in Italy

6.2.3.3. Diagnosed Prevalence of Epidermolysis Bullosa in Italy

6.2.3.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Italy

6.2.4. Spain

6.2.4.1. Assumptions and Rationale

6.2.4.2. Total Prevalent Cases of Epidermolysis Bullosa in Spain

6.2.4.3. Diagnosed Prevalence of Epidermolysis Bullosa in Spain

6.2.4.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Spain

6.2.5. United Kingdom

6.2.5.1. Assumptions and Rationale

6.2.5.2. Total Prevalent Cases of Epidermolysis Bullosa in the United Kingdom

6.2.5.3. Diagnosed Prevalence of Epidermolysis Bullosa in the United Kingdom

6.2.5.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in the United Kingdom

6.3. Japan Epidemiology

6.3.1. Assumptions and Rationale

6.3.2. Total Prevalent Cases of Epidermolysis Bullosa in Japan

6.3.3. Diagnosed Prevalence of Epidermolysis Bullosa in Japan

6.3.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Japan

7. Appendix

7.1. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

List of Table

Table 1: Classification of Epidermolysis Bullosa (EB)

Table 2: Level of Evidence

Table 3: Grades of recommendation made by the guideline panel

Table 4: Level of Evidence

Table 5: Total Prevalent Patient Population of Epidermolysis Bullosa in 7MM (2018–2030)

Table 6: Diagnosed Prevalent Patient Population of Epidermolysis Bullosa in the 7MM (2018–2030)

Table 7: 7MM Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa (2018–2030)

Table 8: Total Prevalent Population of Epidermolysis Bullosa in the United States (2018–2030)

Table 9: Diagnosed Prevalence of Epidermolysis Bullosa in the United States (2018–2030)

Table 10: Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in the United States (2018–2030)

Table 11: Total Prevalent Population of Epidermolysis Bullosa in Germany (2018–2030)

Table 12: Diagnosed Prevalence of Epidermolysis Bullosa in Germany (2018–2030)

Table 13: Type Specific Diagnosed Prevalence of Epidermolysis Bullosa in Germany (2018–2030)

Table 14: Total Prevalent Population of Epidermolysis Bullosa in France (2018–2030)

Table 15: Diagnosed Prevalence of Epidermolysis Bullosa in France (2018–2030)

Table 16: Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in France (2018–2030)

Table 17: Total Prevalent Population of Epidermolysis Bullosa in Italy (2018–2030)

Table 18: Diagnosed Prevalence of Epidermolysis Bullosa in Italy (2018–2030)

Table 19: Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Italy (2018–2030)

Table 20: Total Prevalent Population of Epidermolysis Bullosa in Spain (2018–2030)

Table 21: Diagnosed Prevalence of Epidermolysis Bullosa in Spain (2018–2030)

Table 22: Type Specific Diagnosed Prevalence of Epidermolysis Bullosa in Spain (2018–2030)

Table 23: Total Prevalent Population of Epidermolysis Bullosa in the United Kingdom (2018–2030)

Table 24: Diagnosed Prevalence of Epidermolysis Bullosa in the United Kingdom (2018–2030)

Table 25: Type Specific Diagnosed Prevalence of Epidermolysis Bullosa in the United Kingdom (2018–2030)

Table 26: Total Prevalent Population of Epidermolysis Bullosa in Japan (2018–2030)

Table 27: Diagnosed Prevalence of Epidermolysis Bullosa in Japan (2018–2030)

Table 28: Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Japan (2018–2030)

List of Figures

Figure 1: Blister formation in Epidermolysis bullosa

Figure 2: Some common symptoms of Epidermolysis Bullosa

Figure 3: Types of Epidermolysis Bullosa

Figure 4: Keratin Proteins and EB Simplex

Figure 5: Pathology Outlines

Figure 6: The mechanism of epidermolysis bullosa

Figure 7: Pathogenesis of Epidermolysis Bullosa Acquisita

Figure 8: Total Prevalent Patient Population of Epidermolysis Bullosa in 7MM (2018–2030)

Figure 9: Diagnosed Prevalence of Epidermolysis Bullosa in the 7MM (2018–2030)

Figure 10: 7MM Type Specific Diagnosed Prevalence of Epidermolysis Bullosa (2018–2030)

Figure 11: Total Prevalent Cases of Epidermolysis Bullosa in the United States (2018–2030)

Figure 12: Diagnosed Prevalence of Epidermolysis Bullosa in the United States (2018–2030)

Figure 13: Type Specific Diagnosed Prevalence of Epidermolysis Bullosa in the US (2018–2030)

Figure 14: Total Prevalent Cases of Epidermolysis Bullosa in Germany (2018–2030)

Figure 15: Diagnosed Prevalence of Epidermolysis Bullosa in Germany (2018–2030)

Figure 16: Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Germany (2018–2030)

Figure 17: Total Prevalent Cases of Epidermolysis Bullosa in France (2018–2030)

Figure 18: Diagnosed Prevalence of Epidermolysis Bullosa in France (2018–2030)

Figure 19: Type Specific Diagnosed Prevalence of Epidermolysis Bullosa in France (2018–2030)

Figure 20: Diagnosed Prevalence of Epidermolysis Bullosa in Italy (2018–2030)

Figure 21: Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Italy (2018–2030)

Figure 22: Total Prevalent Cases of Epidermolysis Bullosa in Spain (2018–2030)

Figure 23: Diagnosed Prevalence of Epidermolysis Bullosa in Spain (2018–2030)

Figure 24: Type Specific Diagnosed Prevalence of Epidermolysis Bullosa in Spain (2018–2030)

Figure 25: Total Prevalent Cases of Epidermolysis Bullosa in the United Kingdom (2018–2030)

Figure 26: Diagnosed Prevalence of Epidermolysis Bullosa in the United Kingdom (2018–2030)

Figure 27: Type Specific Diagnosed Prevalence of Epidermolysis Bullosa in the UK (2018–2030)

Figure 28: Total Prevalent Cases of Epidermolysis Bullosa in Japan (2018–2030)

Figure 29: Diagnosed Prevalence of Epidermolysis Bullosa in Japan (2018–2030)

Figure 30: Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Japan (2018–2030)

  • Tags:
  • Epidermolysis Bullosa (EB) Epidemio...
  • Epidermolysis Bullosa (EB)
  • Epidermolysis Bullosa (EB) Pipelin...
  • Epidermolysis Bullosa (EB) Compani...
  • Epidermolysis Bullosa (EB) prevale...
  • Epidermolysis Bullosa (EB) inciden...
  • Epidermolysis Bullosa (EB) patient...
  • Epidermolysis Bullosa (EB) treatme...

Forward to Friend

Need A Quote